Literature DB >> 32965163

Identification of spliceosome components pivotal to breast cancer survival.

Jing An1,2, Zhehui Luo3, Weiwei An1,2, Difei Cao1,2,4, Jianli Ma5, Zhaoliang Liu1,2.   

Abstract

Cancer cells employ alternative splicing (AS) to acquire splicing isoforms favouring their survival. However, the causes of aberrant AS in breast cancer are poorly understood. In this study, the METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) data were analysed with univariate feature selection. Of 122 analysed spliceosome components, U2SURP, PUF60, DDX41, HNRNPAB, EIF4A3, and PPIL3 were significantly associated with breast cancer survival. The top 4 four genes, U2SURP, PUF60, DDX41, and HNRNPAB, were chosen for further analyses. Their expression was significantly associated with cancer molecular subtype, tumour stage, tumour grade, overall survival (OS), and cancer-specific survival in the METABRIC data. These results were verifiable using other cohorts. The Cancer Genome Atlas data unveiled the elevated expression of PUF60, DDX41, and HNRNPAB in tumours compared with the normal tissue and confirmed the differential expression of the four genes among cancer molecular subtypes, as well as the associations of U2SURP, PUF60, and DDX41 expression with tumour stage. A meta-analysis data verified the associations of U2SURP, PUF60, and HNRNPAB expression with tumour grade, the associations of PUF60, DDX41, and HNRNPAB expression with OS and distant metastasis-free survival, and the associations of U2SURP and HNRNPAB expression with relapse-free survival. Experimentally, we demonstrated that inhibiting the expression of the four genes separately suppressed cell colony formation and slowed down cell growth considerably in breast cancer cells, but not in immortal breast epithelial cells. In conclusion, we have identified U2SURP, PUF60, DDX41, and HNRNPAB are spliceosome-related genes pivotal for breast cancer survival.

Entities:  

Keywords:  DDX41; HNRNPAB; PUF60; Spliceosome; U2SURP; breast cancer

Year:  2020        PMID: 32965163     DOI: 10.1080/15476286.2020.1822636

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  3 in total

1.  Identification of tumor biomarkers for pathological complete response to neoadjuvant treatment in locally advanced breast cancer.

Authors:  Prarthana Gopinath; Sridevi Veluswami; Gopal Gopisetty; Shirley Sundersingh; Swaminathan Rajaraman; Rajkumar Thangarajan
Journal:  Breast Cancer Res Treat       Date:  2022-05-21       Impact factor: 4.872

2.  The Functional Impact of Alternative Splicing on the Survival Prognosis of Triple-Negative Breast Cancer.

Authors:  Sijia Wu; Jiachen Wang; Xinchao Zhu; Jacqueline Chyr; Xiaobo Zhou; Xiaoming Wu; Liyu Huang
Journal:  Front Genet       Date:  2021-01-14       Impact factor: 4.599

Review 3.  Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data.

Authors:  Ziqi Wan; Bing Han
Journal:  Ther Adv Hematol       Date:  2021-07-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.